Myeloid leukaemia of Down syndrome: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 1 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Advanced, first line

Newly diagnosed

3 optionsCompare side by side →

Reduced-intensity cytarabine and daunorubicin-based chemotherapy on the AAML0431 model, with measurable residual disease guiding further reduction; no transplant in first remission.

The options, in plain words

CytarabineApprovedPyrimidine nucleoside analogue (antimetabolite)

Cytarabine is the core chemotherapy for acute myeloid leukaemia, given with an anthracycline as the classic 7+3 induction and at high doses for consolidation; it is also injected into the spinal fluid to treat or prevent leukaemia in the brain.

DaunorubicinApprovedAnthracycline (topoisomerase II inhibitor)

Daunorubicin is the anthracycline most often combined with cytarabine to bring acute myeloid leukaemia into remission; it is also part of induction for acute lymphoblastic leukaemia.

MRD / molecular residual disease testingEstablished

An ultra-sensitive blood test after surgery that detects leftover cancer months before a scan would.

Months of lead time over imaging
Enables escalation and de-escalation trials

Also referenced:Acute myeloid leukaemia in children

The evidence behind it

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Phase 3 NCT02521493 2025280 peopleevidence 61
Tests Cytarabine, Daunorubicin
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
No headline result recorded yet.
Event-free Survival (EFS) (%): Arm A (Standard Risk) 89.37 (n=114) vs Arm B (High Risk) 80.49 (n=41) · source

The main trade-offs on record

MRD / molecular residual disease testing

Sensitivity limited by cfDNA quantity
Lead time without proven intervention causes anxiety

Questions to ask about this decision

Between Cytarabine, Daunorubicin and MRD / molecular residual disease testing, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
What is my exact diagnosis, stage, and grade, and which tests established them?
Why: Everything else follows from an accurate stage and subtype.
Which biomarkers have been tested on my tumour (for example Trisomy 21 with somatic GATA1 mutation, Megakaryoblastic morphology and markers, Measurable residual disease by flow cytometry on day 28 of induction, History of transient abnormal myelopoiesis), and what were the results?
Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
Which subtype is my cancer, and does that change the recommended treatment?
Why: Recognised subtypes for this cancer include Myeloid leukaemia of Down syndrome, megakaryoblastic, Myeloid leukaemia of Down syndrome with prior transient abnormal myelopoiesis, Myelodysplasia-related presentation of myeloid leukaemia of Down syndrome.
Is germline (inherited) genetic testing recommended for me or my family?
Why: Inherited variants can change treatment and matter for relatives.
For my situation (newly diagnosed), which of the standard options do you recommend and why?
Why: Guideline options include: Reduced-intensity cytarabine and daunorubicin-based chemotherapy on the AAML0431 model, with measurable residual disease guiding further reduction; no transplant in first remission.
Am I a candidate for Cytarabine, Daunorubicin, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care